Abstract:Despite the current standard of neoadjuvant chemoradiation therapy followed by radical surgery improving outcomes in patients with operable esophageal carcinoma (EC), there are still limited reports of clinical and treatment-related features that might predict pathological complete response (pathCR), which indicated superior survival outcome in many series. The purpose of this study is to evaluate if chemoradiotherapy intensity and other clinical or treatment-related features might predict pathCR and acute toxicity in patients with esophageal cancer who received trimodality therapy. We retrospectively analyzed clinical and treatment-related features of 127 consecutive patients with EC who received trimodality therapy in two tertiary centers between January 2010 and December 2015. Either primary or nodal specimens with no residual carcinoma were defined as pathCR. We applied logistic regressions to identify independent clinical or treatment related features, especially chemoradiotherapy intensity, associated with pathCR and acute toxicity. The receiver-operating characteristic (ROC) curve was also generated to obtain the best cut-off point. With a majority of squamous cell histology (N=124, 97.6%) and male gender (N= 121, 95.3%), all patients received neoadjuvant therapy with cisplatin and fluorouracil chemotherapy and radiotherapy. A pathCR was achieved in 47 (37%) of 127 patients. Low-grade tumors (odds ratio [OR]: 32.279; p < .0001) and cumulative cisplatin dose (mg/m2) during radiotherapy (OR: 1.031; p < .0001, cut-off point: 128.5 mg/m2) significantly predicted higher pathCR rates in multivariate logistic regression models. A lower pathCR rate was observed in patients with greater body weight loss (by percentage) during neoadjuvant therapy (OR: 0.865, p= .010, cut-off point: 8.85%). Meanwhile, the higher radiation dose to gross tumors was not associated with pathCR (OR: 1.000, p= .374), but was the only independent factor that significantly predicted severe (≥ grade 3) acute hematologic toxicity (OR: 1.002, p< .001, cut-off point: 5200 cGy). Low-grade tumors and cumulative cisplatin dose during radiotherapy were predictive of a higher possibility of pathCR. Greater body weight lost during neoadjuvant therapy was a negative predictor for pathCR. Increasing radiation dose did not contribute to pathCR, but did increase the severity of acute hematologic toxicity. Interventions that improve treatment tolerance as per protocol and nutrition status during neoadjuvant therapy are needed to achieve higher pathCR rates and potentially better outcomes.

Clinical Predictors of Pathologically Response after Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Long Term Outcomes of a Phase II Study.

Impact of Pathological Response and Recurrence Pattern on the Survival of Patients Who Develop Recurrence from Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC).

Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis

Improved Prognosis with Induction Chemotherapy in Pathological Complete Responders after Trimodality Treatment for Esophageal Squamous Cell Carcinoma: Hypothesis Generating for Adjuvant Treatment.

Long-Term Survival and Recurrence Patterns in Locally Advanced Esophageal Squamous Cell Carcinoma Patients with Pathologic Complete Response After Neoadjuvant Chemotherapy Followed by Surgery

A Phase II Study of Early FDG-PET Evaluation after One-Cycle Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy: Final Report.

Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma

Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010)

Is There a Correlation Between Clinical Complete Response and Pathological Complete Response after Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?

Oncologic Outcome of Patients With Pathologic T0 Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy

Impact of Chemoradiotherapy Intensity on Pathological Complete Response in Patients with Esophageal Cancer Receiving Trimodality Therapy

Clinical Significance of Risk Stratification of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiation and Surgery

Is Pathologic Complete Response a Good Predictor for the Long-Term, Clinical Outcome in Patients with Gastric Cancer After Neoadjuvant Chemotherapy? A Retrospective, Multi-institution Study in China

Genomic characteristics in neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers.

430. PROGNOSTIC PATTERNS OF LYMPH NODES WITH COMPLETE TREATMENT RESPONSE IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER NEOADJUVANT CHEMORADIOTHERAPY AND NEOADJUVANT CHEMOTHERAPY

The patterns and risk factors for relapse in oesophageal squamous cell cancers that achieve pathological complete response to neoadjuvant chemoradiotherapy

Prognostic factors for survival in esophageal squamous cell carcinoma (ESCC) patients with a complete regression of the primary tumor (ypT0) after neoadjuvant chemoradiotherapy (NCRT) followed by surgery

Response to Comment on “prognostic Impact of Postoperative Lymph Node Metastases after Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus”

Prognostic factors for survival in esophageal squamous cell carcinoma (ESCC) patients with a complete regression of the primary tumor (ypTO) after neoadjuvant chemoradiotherapy (NCRT) followed by surgery

Prognostic Impact of Inflammation-Based Factors in Patients with Esophageal Squamous Cell Carcinoma Achieving Pathological Complete Response After Neoadjuvant Chemoradiotherapy Followed by Surgery